Django Sussman

This inventor holds 20 USPTO granted patents and 22 published patent applications, plus 8 CIPO patents and 10 EPO patents, primarily in Antibody Engineering. Top assignees: Seattle Genetics, Inc., Seagen Inc.. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Django Sussman. Retrieved from https://idiyas.com/inventor/django-sussman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 8 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 3.9

ph-index = 6

Forward Citations = 157(Granted Patents)

Location History:

Seattle, WA (US) (2013 - 2023)
Bothell, WA (US) (2012 - 2024)

Company Filing History:

13 out of 132

Seattle Genetics, Inc.

Years Active: 2012-2024

Loading Chart...

Areas of Expertise:

Cysteine Mutated Antibodies

BCMA Antibodies

Anti-NTB-A Antibodies

LIV1-ADC

Core Fucosylation

Humanized Antibodies

CD123 Antibodies

CD33 Antibodies

Combination Therapy

Cancer Treatment

Immunological Disorders

Target Binding Agents

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11938194 - Cysteine mutated antibodies for conjugation (2024-03-26),

2. 11767365 - BCMA antibodies and use of same to treat cancer and immunological disorders (2023-09-26),

3. 11351269 - Anti-NTB-A antibodies and related compositions and methods (2022-06-07),

4. 11325980 - Combination therapy using a LIV1-ADC and a chemotherapeutic (2022-05-10),

5. 11319526 - Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation (2022-05-03),

6. RE48959 - Humanized antibodies to LIV-1 and use of same to treat cancer (2022-03-07),

7. 11078291 - BCMA antibodies and use of same to treat cancer and immunological disorders (2021-08-03),

8. 10912842 - CD123 antibodies and conjugates thereof (2021-02-09),

9. 10787514 - CD33 antibodies and use of same to treat cancer (2020-09-29),

10. 10443035 - Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation (2019-10-15),

11. 10407505 - Variant target binding agents and uses thereof (2019-09-10),

12. 9816069 - Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation (2017-11-14),

13. 9783608 - Humanized antibodies to LIV-1 and use of same to treat cancer (2017-10-10),

14. 9587019 - CD33 antibodies and use of same to treat cancer (2017-03-07),

15. 9228026 - Humanized antibodies to LIV-1 and use of same to treat cancer (2016-01-05),

Title: The Innovative Journey of Django Sussman

Introduction: Django Sussman, a talented inventor hailing from Bothell, WA, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Django Sussman's latest patents focus on advancements in renewable energy technologies, particularly in the field of solar power storage and efficiency.

Career Highlights: With a career spanning over two decades, Django Sussman has worked for several prominent tech companies, leading research and development teams to create cutting-edge solutions in the renewable energy sector.

Collaborations: Throughout his career, Django Sussman has collaborated with top researchers and engineers in the industry, fostering a culture of innovation and pushing the boundaries of what is possible in the field of renewable energy.

Conclusion: Django Sussman's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and engineers. His impact on the renewable energy sector is truly remarkable, and his legacy will undoubtedly endure for years to come.

Profile summary based on public USPTO records.